Hafslund Nycomed/Diatech deal gives Nycomed first access to peptide-based nuclear imaging agents.
HAFSLUND NYCOMED/DIATECH COLLABORATION ON IMAGING AGENTS is the Norwegian firm Hafslund Nycomed's first venture into nuclear medicines, the companies said Aug. 14. Nycomed is the largest medical imaging contrast media company in the world, and through a $10 mil. equity investment in Londonderry, N.H.-based Diatech, it will have access to Diatech's proprietary TechTide peptide-based nuclear medicine imaging agents.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth